GlassScriptPhysician profile
Ghulam Qadir
NPI 1770662165
$584.65
in general payments reported to CMS, 2019-2025
16 companies · $28.68 in 2025
The $28.68 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2021: $63.40 · 2022: $79.20 · 2023: $233 · 2025: $28.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120.16 | 2023 | |
| Supernus Pharmaceuticals, INC. | $103.44 | 2022-2023 | Qelbree |
| Alkermes, INC. | $47.69 | 2021 | |
| Allergan, INC. | $44.28 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.11 | 2021-2023 | |
| Axsome Therapeutics, INC. | $28.68 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $28.43 | 2019 | |
| Indivior INC. | $27.54 | 2023 | Perseris |
| Ironshore Pharmaceuticals INC. | $26.46 | 2019 | |
| Lundbeck LLC | $26.11 | 2019 | |
| Corium, LLC | $25.33 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $23.96 | 2019 | |
| Tris Pharma INC | $14.59 | 2019 | |
| Shire North American Group INC | $12.62 | 2019 | |
| Almatica Pharma LLC | $12.15 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $4.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.